Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 6, Pages 1691-1697
Publisher
Oxford University Press (OUP)
Online
2013-02-14
DOI
10.1093/annonc/mdt015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing SelectiveBRAFInhibition
- (2012) Lisa Zimmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Ultraviolet A and Photosensitivity during Vemurafenib Therapy
- (2012) Reinhard Dummer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming metastatic melanoma with BRAF inhibitors
- (2011) Seunghee Hong et al. ARCHIVES OF PHARMACAL RESEARCH
- Skin Tumors Induced by Sorafenib; Paradoxic RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1
- (2011) J. P. Arnault et al. CLINICAL CANCER RESEARCH
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysis
- (2009) I. Tsoumpou et al. CANCER TREATMENT REVIEWS
- Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib
- (2009) Jean Philippe Arnault et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor
- (2008) Julien Autier et al. ARCHIVES OF DERMATOLOGY
- Sorafenib-Induced Eruptive Melanocytic Lesions
- (2008) Heidi H. Kong et al. ARCHIVES OF DERMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started